Research Paper Volume 2, Issue 11 pp 791—803

Figure 4. Intracranial regression of tumor growth by hUCBSC. (A) Nude mice with pre-established intracranial human glioma tumors (U251 or 5310) were treated with hUCBSC by intracranial injection (2x10⁵). Fourteen days after hUCBSC administration, the brains were harvested, sectioned, and stained with Hematoxylin and Eosin. Bar = 2000μm (B) Characterization of hUCBSC in nude mice brain sections: Fourteen days after hUCBSC administration, the brains were harvested, sectioned and immunoprobed with mesenchymal stem cell markers CD29 using Alexa fluor-594 secondary antibody. (n = 3). Scale bar = 100μm.